
Novartis narrowed its mid-term sales growth outlook to 5% annually through 2031 at its London investor day, as patent expirations weigh on the Swiss drugmaker.
Piramal Pivots for Growth
over 14 years ago
Country Report: Mexicoover 14 years ago
Sunny Outlook for Biopharm 2020?over 14 years ago
The Phrase that Playsover 14 years ago
Planning that Thousand Year Future





